Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder

Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20571180

Indexing Status
Subject indexing assigned by NLM

MeSH
Absenteeism; Algorithms; Antidepressive Agents, Second-Generation /economics /therapeutic use; Azabicyclo Compounds /economics /therapeutic use; Cost of Illness; Cost-Benefit Analysis; Depressive Disorder, Major /diagnosis /drug therapy /economics; Double-Blind Method; Drug Costs /statistics & numerical data; Eszopiclone; Fluoxetine /economics /therapeutic use; Humans; Hypnotics and Sedatives /economics /therapeutic use; Personality Inventory /statistics & numerical data; Piperazines /economics /therapeutic use; Psychometrics /statistics & numerical data; Quality-Adjusted Life Years

AccessionNumber
22010001099

Date bibliographic record published
29/09/2010